A Rocket Pharmaceuticals gene therapy for the rare immune disorder leukocyte adhesion deficiency-I has met the survival goals of a pivotal study, paving the way for regulatory submissions that the company expects to file in early 2023.
In this free webinar on June 9th, industry experts from Syneos and Medable will share their perspectives on how to address these drug development challenges within cardiometabolic clinical studies and provide input on the impact of new regulatory guidance such as the DEPICT Act. This engaging panel will discuss leveraging technology and home health solutions to augment existing points of care between patients and their clinical care team to improve the patient experience, drive more scientific rigor to data generation and achieve timely endpoint capture.
The startup—which has twice received KLAS Research's "Best in KLAS" award for patient outreach—will use funds its raised to grow the number of teams working on its patient communication solutions.
Mechanical thrombectomy is a minimally invasive procedure that offers positive benefits to ischemic stroke patients – which account for 85 percent of all strokes – in the first few hours after stroke onset.
No comments